D.E. Shaw & Co’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.33M Buy
1,003,912
+280,695
+39% +$2.91M 0.01% 1793
2025
Q4
$8.94M Buy
723,217
+402,050
+125% +$4.31M ﹤0.01% 1862
2025
Q3
$2.83M Sell
321,167
-90,201
-22% -$702K ﹤0.01% 2706
2025
Q2
$2.62M Buy
411,368
+139,094
+51% +$796K ﹤0.01% 2541
2025
Q1
$1.32M Sell
272,274
-110,769
-29% -$917K ﹤0.01% 2899
2024
Q4
$3.66M Sell
383,043
-388,095
-50% -$3.56M ﹤0.01% 2240
2024
Q3
$6.44M Sell
771,138
-56,658
-7% -$515K 0.01% 1756
2024
Q2
$5.65M Buy
827,796
+411,132
+99% +$1.77M 0.01% 1755
2024
Q1
$1.05M Sell
416,664
-769,888
-65% -$1.74M ﹤0.01% 3062
2023
Q4
$2.85M Buy
1,186,552
+250,034
+27% +$588K ﹤0.01% 2389
2023
Q3
$3.18M Sell
936,518
-41,399
-4% -$229K ﹤0.01% 2212
2023
Q2
$7.19M Sell
977,917
-385,863
-28% -$3.58M 0.01% 1610
2023
Q1
$14.1M Sell
1,363,780
-267,838
-16% -$3.24M 0.02% 1114
2022
Q4
$19.3M Buy
1,631,618
+639,405
+64% +$9.89M 0.02% 950
2022
Q3
$20.8M Sell
992,213
-73,734
-7% -$2.05M 0.02% 822
2022
Q2
$33.1M Sell
1,065,947
-97,639
-8% -$3.33M 0.04% 589
2022
Q1
$47.8M Buy
1,163,586
+218,248
+23% +$9.63M 0.04% 511
2021
Q4
$41.1M Buy
945,338
+882,893
+1,414% +$39.9M 0.03% 656
2021
Q3
$3.13M Buy
62,445
+52,852
+551% +$3.2M ﹤0.01% 2586
2021
Q2
$604K Buy
+9,593
New +$616K ﹤0.01% 3934
2021
Q1
Sell
-12,991
Closed -$1.16M 4148
2020
Q4
$1.16M Buy
+12,991
New +$1.19M ﹤0.01% 2928
2020
Q3
Sell
-7,954
Closed -$629K 3914
2020
Q2
$629K Sell
7,954
-37,703
-83% -$2.81M ﹤0.01% 3209
2020
Q1
$2.64M Sell
45,657
-51,701
-53% -$2.98M ﹤0.01% 1954
2019
Q4
$5.25M Sell
97,358
-17,857
-15% -$969K 0.01% 1692
2019
Q3
$6.02M Buy
115,215
+76,298
+196% +$3.55M 0.01% 1507
2019
Q2
$1.88M Sell
38,917
-26,555
-41% -$1.27M ﹤0.01% 2281
2019
Q1
$3.31M Sell
65,472
-35,103
-35% -$2.07M ﹤0.01% 1812
2018
Q4
$5.96M Sell
100,575
-24,998
-20% -$1.61M 0.01% 1412
2018
Q3
$8.27M Sell
125,573
-15,254
-11% -$890K 0.01% 1228
2018
Q2
$7.11M Sell
140,827
-38,420
-21% -$2M 0.01% 1299
2018
Q1
$9.44M Sell
179,247
-66,332
-27% -$3.31M 0.01% 1036
2017
Q4
$11.4M Sell
245,579
-51,702
-17% -$2.18M 0.02% 956
2017
Q3
$12M Sell
297,281
-79,631
-21% -$2.88M 0.02% 832
2017
Q2
$12.8M Sell
376,912
-28,399
-7% -$877K 0.02% 779
2017
Q1
$11.8M Sell
405,311
-254,486
-39% -$7.75M 0.02% 811
2016
Q4
$21.7M Buy
659,797
+126,148
+24% +$3.78M 0.04% 594
2016
Q3
$16.8M Sell
533,649
-308,924
-37% -$8.98M 0.03% 651
2016
Q2
$23.7M Sell
842,573
-49,303
-6% -$1.93M 0.04% 486
2016
Q1
$32.4M Buy
891,876
+31,180
+4% +$1.1M 0.06% 383
2015
Q4
$34.4M Buy
860,696
+98,910
+13% +$3.45M 0.05% 419
2015
Q3
$21.7M Buy
761,786
+114,028
+18% +$3.76M 0.03% 586
2015
Q2
$21.3M Buy
647,758
+40,339
+7% +$1.25M 0.03% 613
2015
Q1
$17.5M Buy
607,419
+46,301
+8% +$1.33M 0.03% 651
2014
Q4
$15.3M Buy
561,118
+40,642
+8% +$969K 0.02% 854
2014
Q3
$11.1M Buy
520,476
+29,729
+6% +$681K 0.01% 1020
2014
Q2
$11M Buy
490,747
+28,199
+6% +$657K 0.02% 1040
2014
Q1
$11.7M Sell
462,548
-10,426
-2% -$263K 0.02% 955
2013
Q4
$10.9M Buy
472,974
+4,904
+1% +$102K 0.01% 1081
2013
Q3
$8.92M Sell
468,070
-32,756
-7% -$585K 0.01% 1101
2013
Q2
$7.22M Buy
+500,826
New +$7.25M 0.01% 1095

Other funds holding EBS

D.E. Shaw & Co's EBS Position: Q1 2026 in Review

D.E. Shaw & Co increased its Emergent Biosolutions (EBS) stake by 39% in Q1 2026, buying an estimated $2.91M and bringing the position to 1,003,912 shares worth $8.33M. The position accounts for 0.01% of the portfolio, ranked #1793.

D.E. Shaw & Co first reported a position in EBS in Q2 2013 and has held it in 50 quarters since. The position peaked at $47.8M in Q1 2022. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

  • D.E. Shaw & Co held 1,003,912 shares of Emergent Biosolutions worth $8.33M as of Q1 2026.
  • D.E. Shaw & Co bought 280,695 Emergent Biosolutions shares in Q1 2026, an estimated $2.91M.
  • Emergent Biosolutions made up 0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1793 holding.
  • D.E. Shaw & Co first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 50 quarters since.
  • D.E. Shaw & Co's Emergent Biosolutions position peaked at $47.8M in Q1 2022.
  • 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.